Aktiesnakken — September 2013
-
genmab over 190
-
det her er et ret stort setback og er nok også baggrunden for udskiftningen af cso?
-
aka Zealand har jo ikke haft noget med Lyxumia at gøre i 5 år
så det må være Sanofi CSO der skal fyres -
kan det ikke være protokollen?
-
─ Sanofi beslutning skyldes ikke sikkerhedsspørgsmål eller mangler i
ansøgningen, og genindsendelsen er planlagt til 2015
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind